Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design-Reference-Cited by-同舟云学术

Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design

Published:2021-09-20 Issue:19 Volume:64 Page:14247-14265
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Gavai Ashvinikumar V.¹^ORCID,Norris Derek¹,Delucca George¹,Tortolani David¹,Tokarski John S.¹,Dodd Dharmpal¹,O’Malley Daniel¹,Zhao Yufen¹,Quesnelle Claude¹,Gill Patrice¹,Vaccaro Wayne¹,Huynh Tram¹,Ahuja Vijay¹,Han Wen-Ching¹,Mussari Christopher¹,Harikrishnan Lalgudi¹,Kamau Muthoni¹,Poss Michael¹,Sheriff Steven¹,Yan Chunhong¹,Marsilio Frank¹,Menard Krista¹,Wen Mei-Li¹,Rampulla Richard¹,Wu Dauh-Rurng¹,Li Jianqing¹^ORCID,Zhang Huiping¹,Li Peng¹,Sun Dawn¹,Yip Henry¹,Traeger Sarah C.¹,Zhang Yingru¹,Mathur Arvind¹,Zhang Haiying¹,Huang Christine¹,Yang Zheng¹,Ranasinghe Asoka¹,Everlof Gerry¹,Raghavan Nirmala¹,Tye Ching Kim¹,Wee Susan¹,Hunt John T.¹,Vite Gregory¹,Westhouse Richard¹,Lee Francis Y.¹

Affiliation:

1. Research and Development, Bristol Myers Squibb Company, P. O. Box 4000, Princeton, New Jersey 08543-4000, United States

Funder

Office of Science

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00625

Reference34 articles.

1. Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches